Abstract
Cerebral Aspergillosis is the most lethal manifestation of infection due to Aspergillus species arising most commonly as hematogenous dissemination from a pulmonary focus, direct extension from paranasal sinus infection or direct inoculation through trauma and surgery of the central nervous system (CNS). Voriconazole is currently considered the standard of treatment of CNS aspergillosis with liposomal amphotericin B being the next best alternative. Neurosurgical resection of infected cerebral tissue in addition to antifungal therapy is frequently performed in patients with CNS aspergillosis to prevent neurological deficits and improve outcome.
Aspergillus endophthalmitis may occur endogenously mostly from a pulmonary focus or exogenously following eye surgery or trauma. Although amphotericin B is still described as the primary therapy, voriconazole is increasingly considered the first line treatment of Aspergillus endophthalmitis. Vitrectomy is recommended in most cases of Aspergillus endophthalmitis.
Keywords: Aspergillus, invasive aspergillosis, endophthalmitis, central nervous system, CNS infection, blood brain barrier, CSF levels, tissue levels, voriconazole, posaconazole, amphotericin B, liposomal amphotericin B, echinocandin, itraconazole, epidemiology, surgery, surgical, neurosurgical, vitrectomy, intravitreal.
Current Pharmaceutical Design
Title:Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Volume: 19 Issue: 20
Author(s): Martin Hoenigl and Robert Krause
Affiliation:
Keywords: Aspergillus, invasive aspergillosis, endophthalmitis, central nervous system, CNS infection, blood brain barrier, CSF levels, tissue levels, voriconazole, posaconazole, amphotericin B, liposomal amphotericin B, echinocandin, itraconazole, epidemiology, surgery, surgical, neurosurgical, vitrectomy, intravitreal.
Abstract: Cerebral Aspergillosis is the most lethal manifestation of infection due to Aspergillus species arising most commonly as hematogenous dissemination from a pulmonary focus, direct extension from paranasal sinus infection or direct inoculation through trauma and surgery of the central nervous system (CNS). Voriconazole is currently considered the standard of treatment of CNS aspergillosis with liposomal amphotericin B being the next best alternative. Neurosurgical resection of infected cerebral tissue in addition to antifungal therapy is frequently performed in patients with CNS aspergillosis to prevent neurological deficits and improve outcome.
Aspergillus endophthalmitis may occur endogenously mostly from a pulmonary focus or exogenously following eye surgery or trauma. Although amphotericin B is still described as the primary therapy, voriconazole is increasingly considered the first line treatment of Aspergillus endophthalmitis. Vitrectomy is recommended in most cases of Aspergillus endophthalmitis.
Export Options
About this article
Cite this article as:
Hoenigl Martin and Krause Robert, Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis, Current Pharmaceutical Design 2013; 19 (20) . https://dx.doi.org/10.2174/13816128113199990342
DOI https://dx.doi.org/10.2174/13816128113199990342 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry Effect of Silver Nanoparticles (AgNPs) on <i>Candida albicans, Candida dubliniensis</i> and <i>Candida guilliermondii</i>
Current Drug Therapy Vaccines and Photodynamic Therapies for Oral Microbial-Related Diseases
Current Drug Metabolism The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Immunoinformatic Approach for the Identification of Potential Epitopes Against <i>Stenotrophomonas maltophilia</i>: A Global Opportunistic Pathogen
Letters in Drug Design & Discovery Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Drugs in Pediatric Ischemic Stroke
Current Drug Targets Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry Protein Preparation, Crystallization and Preliminary X-Ray Crystallographic Analysis of N-Acetylglutamate Kinase from Streptococcus mutans
Protein & Peptide Letters Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epidemiological Review of Gonococcal Infection
Current Women`s Health Reviews Cefixime-induced Oromandibular Dystonia in an Adult: A Case Report
Current Drug Safety Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Complementary Therapies in Inflammatory Bowel Diseases
Current Drug Targets